ATE551363T1 - Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen - Google Patents

Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen

Info

Publication number
ATE551363T1
ATE551363T1 AT01952133T AT01952133T ATE551363T1 AT E551363 T1 ATE551363 T1 AT E551363T1 AT 01952133 T AT01952133 T AT 01952133T AT 01952133 T AT01952133 T AT 01952133T AT E551363 T1 ATE551363 T1 AT E551363T1
Authority
AT
Austria
Prior art keywords
antibodies
interleukin
receptor
compositions
bind
Prior art date
Application number
AT01952133T
Other languages
English (en)
Inventor
John Pluenneke
Richard J Armitage
Jose Carlos Escobar
Arvia E Morris
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27504940&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE551363(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/785,934 external-priority patent/US20020002132A1/en
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE551363T1 publication Critical patent/ATE551363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT01952133T 2000-05-26 2001-05-25 Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen ATE551363T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57980800A 2000-05-26 2000-05-26
US66534300A 2000-09-19 2000-09-19
US09/785,934 US20020002132A1 (en) 2000-05-26 2001-02-15 Use of interleukin-4 antagonists and compositions thereof
US84781601A 2001-05-01 2001-05-01
PCT/US2001/017094 WO2001092340A2 (en) 2000-05-26 2001-05-25 Use of interleukin-4 antagonists and compositions thereof

Publications (1)

Publication Number Publication Date
ATE551363T1 true ATE551363T1 (de) 2012-04-15

Family

ID=27504940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01952133T ATE551363T1 (de) 2000-05-26 2001-05-25 Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen

Country Status (12)

Country Link
US (8) US7186809B2 (de)
EP (4) EP2990420B1 (de)
AT (1) ATE551363T1 (de)
AU (1) AU2001272925A1 (de)
CA (1) CA2409267C (de)
CY (1) CY1118951T1 (de)
DE (1) DE16192152T1 (de)
DK (1) DK2990420T3 (de)
ES (3) ES2382891T3 (de)
MX (1) MXPA02011682A (de)
PT (1) PT2990420T (de)
WO (1) WO2001092340A2 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277460T3 (es) 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US7553487B2 (en) 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
WO2003092610A2 (en) 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
NZ548821A (en) * 2004-02-06 2009-12-24 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP2366786A3 (de) * 2005-05-05 2012-08-29 VALORISATION HSJ, Société en Commandite Zytokin-Rezeptormodulatoren und Verwendung davon
GB0510790D0 (en) 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2008054606A2 (en) * 2006-10-02 2008-05-08 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
RU2490278C2 (ru) * 2007-12-21 2013-08-20 Медиммун Лимитед ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
US20110008326A1 (en) * 2008-04-02 2011-01-13 Oliver Hill Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
WO2011106779A1 (en) * 2010-02-26 2011-09-01 Aerovance Inc. Use of modified il-4 mutien receptor antagonists to treat dermatitis
PL2624865T3 (pl) 2010-10-06 2018-11-30 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny-4 (IL-4R)
CN103930444B (zh) 2011-09-16 2020-08-04 瑞泽恩制药公司 用前蛋白转化酶枯草溶菌素-9(PCSK9)抑制剂降低脂蛋白(a)水平的方法
EP2596802A1 (de) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmazeutische Zusammensetzung zur Behandlung allergischer Reaktionen
WO2014031610A1 (en) 2012-08-21 2014-02-27 Sanofi Methods for treating or preventing asthma by administering an il-4r antagonist
HRP20181227T1 (hr) 2012-09-07 2018-10-05 Regeneron Pharmaceuticals, Inc. Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
CN103289962B (zh) * 2012-12-07 2015-03-18 天津三箭生物技术有限公司 小鼠抗人cd23单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
PT3613432T (pt) 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
WO2016023916A1 (en) 2014-08-12 2016-02-18 Kymab Limited Treatment of disease using ligand binding to targets of interest
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
WO2016071701A1 (en) 2014-11-07 2016-05-12 Kymab Limited Treatment of disease using ligand binding to targets of interest
US10066017B2 (en) 2014-11-14 2018-09-04 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2017102920A1 (en) 2015-12-18 2017-06-22 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
MA44238B1 (fr) 2016-02-19 2024-07-31 Regeneron Pharmaceuticals, Inc. Procédés d'augmentation de l'efficacité d'un vaccin par administration d'un antagoniste d'il-4r
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
CN109789196B (zh) 2016-09-01 2024-03-19 瑞泽恩制药公司 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
CN118203659A (zh) 2016-09-22 2024-06-18 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗严重特应性皮炎的方法
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
BR112019021812A2 (pt) 2017-04-21 2020-05-26 Kindred Biosciences, Inc. Molécula receptora de il4/il13 para uso veterinário
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
PL3703818T3 (pl) 2017-10-30 2024-03-25 Sanofi Biotechnology Antagonista IL-4R do zastosowania w sposobie leczenia lub zapobiegania astmie
KR20200135781A (ko) 2018-03-26 2020-12-03 암젠 인크 세포 배양에서 생산된 항체의 총 비푸코실화 당형태
EP3793597A1 (de) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung atopischer dermatitis durch verabreichung eines il-4r-inhibitors
CN113101364B (zh) 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
BR112021002989A2 (pt) 2018-08-24 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. anticorpo para ligação de il-4r de humano, fragmento para ligação de antígeno e uso médico do mesmo
WO2020086886A1 (en) 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
CN111494625B (zh) 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
SG11202106990PA (en) * 2018-12-28 2021-07-29 Kyowa Kirin Co Ltd BISPECIFIC ANTIBODY BINDING TO TfR
SG11202109003QA (en) 2019-03-06 2021-09-29 Regeneron Pharma Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN114173819A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
MX2022003461A (es) 2019-09-26 2022-04-19 Amgen Inc Metodos de produccion de composiciones de anticuerpos.
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
EP3992974A1 (de) 2020-11-02 2022-05-04 Sanofi Biotechnology Verfahren zur behandlung von digital identifizierten il-4/il-13-bedingten erkrankungen
EP4073810A1 (de) 2019-12-09 2022-10-19 Sanofi Biotechnology Verfahren zur behandlung von digital identifizierten il-4/il-13-bedingten erkrankungen
AU2021223128A1 (en) 2020-02-21 2022-09-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-IL-4R antibody and use thereof
WO2021195530A1 (en) 2020-03-27 2021-09-30 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
CN113527485B (zh) 2020-04-17 2024-11-15 湖南麦济生物技术股份有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用
KR20230015965A (ko) 2020-05-22 2023-01-31 리제너론 파아마슈티컬스, 인크. Il-4r 억제제를 투여함에 의해 호산구성 식도염을 치료하기 위한 방법
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
TW202231663A (zh) 2020-12-22 2022-08-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ－４ｒ抗體或其抗原結合片段的複合物及醫藥用途
WO2022150605A1 (en) 2021-01-08 2022-07-14 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
CN116745324A (zh) 2021-01-27 2023-09-12 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
US12365739B2 (en) * 2021-03-24 2025-07-22 Wake Forest University Health Sciences Monoclonal antibodies to angiotensin-(1-12), compositions including the same, and methods of use thereof
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
JP2024532263A (ja) 2021-08-23 2024-09-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによってアトピー性皮膚炎を治療する方法
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
AU2022425608A1 (en) 2021-12-30 2024-08-15 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
EP4470569A1 (de) 2022-01-29 2024-12-04 Shanghai Shengdi Pharmaceutical Co., Ltd Glucocorticoid-wirkstoffkonjugat
EP4518839A2 (de) 2022-05-02 2025-03-12 Regeneron Pharmaceuticals, Inc. Verfahren zur reduzierung der lipaseaktivität
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
CA3250514A1 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. ANTI-INTERLEUKIN-4 (IL-4R) RECEPTOR ANTIBODIES
MA71395A (fr) 2022-07-08 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles chez un sujet pédiatrique par administration d'un antagoniste d'il-4 r
WO2024097714A1 (en) 2022-11-01 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods for treating hand and foot dermatitis by administering an il-4r antagonist
WO2024112935A1 (en) 2022-11-23 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
TW202502820A (zh) 2023-03-27 2025-01-16 美商再生元醫藥公司 藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
CN121568722A (zh) 2023-07-28 2026-02-24 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
US20260070995A1 (en) 2024-09-09 2026-03-12 Marcella Ruddy Methods for treating bullous pemphigoid by administering an il-4r antagonist

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US5041381A (en) 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
JPH03500050A (ja) 1988-02-02 1991-01-10 シェリング・バイオテック・コーポレーション 免疫グロブリンｅの応答を減少させる方法
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
PT96230B (pt) 1989-12-20 1998-06-30 Schering Corp Processo para a producao de um polipeptideo e anticorpos antagonistas da interleuquina-4 humana
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
DK0835939T3 (da) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusionsproteiner med andele af immunglobulin, deres fremstilling og anvendelse
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE4137333A1 (de) 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
NZ249677A (en) 1992-02-19 1996-08-27 Schering Corp Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies
WO1993018047A1 (en) 1992-03-09 1993-09-16 Ludwig Institute For Cancer Research Nucleic acid sequences coding for or complementary to nucleic acid sequences coding for interleukin 9 receptor
JP3255699B2 (ja) 1992-04-23 2002-02-12 味の素株式会社 ヒトＩＬ−２レセプターγ鎖分子
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5472866A (en) 1992-12-24 1995-12-05 Synaptic Pharmaceutical Corporation DNA encoding 5-HT4A serotonin receptors
EP0604693A1 (de) 1992-12-29 1994-07-06 Schering-Plough Monoklonale Antikörper gegen den menschlichen Interleukin-4-Rezeptor und Hybridomen die diese produzieren
EP0689451A4 (de) * 1993-03-19 1997-08-20 Immunex Corp Pharmazeutische zubereitungen, die einen liganden enthalten, der mit einem löslichen rezeptor komplexiert ist
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5928904A (en) 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1996011213A1 (en) 1994-10-07 1996-04-18 Amgen Boulder Inc. Dimeric il-4 inhibitors
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
EP0822830B1 (de) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5855918A (en) 1995-09-12 1999-01-05 Genentech, Inc. Cystic fibrosis therapy
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
DE16192152T1 (de) 2000-05-26 2020-08-06 Immunex Corporation Verwendung von interleukin-4 rezeptor (il-4r) antikörpern und zusammensetzungen davon
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
GEP20104991B (en) 2003-11-07 2010-05-25 Immunex Corp Antibodies that bind interleukin-4 receptor
US20080124340A1 (en) 2006-04-14 2008-05-29 Borges Luis G Erythropoietin receptor agonists
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)

Also Published As

Publication number Publication date
CA2409267C (en) 2017-02-28
US8679487B2 (en) 2014-03-25
WO2001092340A2 (en) 2001-12-06
ES2614260T3 (es) 2017-05-30
CA2409267A1 (en) 2001-12-06
DK2990420T3 (en) 2017-04-03
EP1283851B1 (de) 2012-03-28
US20070041976A1 (en) 2007-02-22
EP2292665B1 (de) 2015-07-08
ES2549767T3 (es) 2015-11-02
MXPA02011682A (es) 2003-05-14
ES2382891T3 (es) 2012-06-14
US20170137526A1 (en) 2017-05-18
US20090104662A1 (en) 2009-04-23
DE16192152T1 (de) 2020-08-06
EP2292665A1 (de) 2011-03-09
US20110002913A1 (en) 2011-01-06
US20030124121A1 (en) 2003-07-03
US9587026B2 (en) 2017-03-07
EP2990420A1 (de) 2016-03-02
US20140154267A1 (en) 2014-06-05
US7465450B2 (en) 2008-12-16
AU2001272925A1 (en) 2001-12-11
EP2990420B1 (de) 2016-12-21
US7186809B2 (en) 2007-03-06
EP1283851A2 (de) 2003-02-19
WO2001092340A3 (en) 2002-04-25
CY1118951T1 (el) 2018-01-10
EP3190126A1 (de) 2017-07-12
US20190023798A1 (en) 2019-01-24
US20180171016A1 (en) 2018-06-21
PT2990420T (pt) 2017-03-16

Similar Documents

Publication Publication Date Title
ATE551363T1 (de) Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen
DE602004025332D1 (de) Antikörper gegen il21-rezeptor und deren verwendung
ATE533508T1 (de) Cripto-blockierende antikörper und ihre verwendung
DE60141603D1 (de) Neue mandelsäurederivate und deren verwendung als thrombininhibitoren
DE60140383D1 (de) Zementdispergiermittel und dieses enthaltende Zementzusammensetzung
DE60138711D1 (de) Antikörper gegen il-12, zusammensetzungen, verfahren und verwendungen
ATE551322T1 (de) 3-z-1-(4-(n-((4-methylpiperazin-1- yl)methylcarbonyl)-n-methylamino)anilino)1- phenylmethylen-6-methoxycarbonyl-2- indolinonmonoethansulfonat und dessen verwendung als pharmazeutische zusammensetzung
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE60237270D1 (de) Kosmetische Zusammensetzungen, die Aminosilikone und Konditionierungsmittel enthalten, und deren Verwendung
EP1501545A4 (de) Verwendung von tnfalpha-antikörpern und eines anderen arzneimittels
ATE459374T1 (de) Polypeptide enthaltende zusammensetzungen
DE60039589D1 (de) Rekombinante il-18 antikörper und deren verwendung
ATE271066T1 (de) Lösliche mutante ctla4 moleküle und deren verwendung
DE602004017614D1 (de) Antikörper gegen den insulinähnlichen wachstumfaktor-i-rezeptor und verwendungen dafür
ATE470714T1 (de) Antikörper gegen doppelintegrinen, zusammensetzungen, verfahren und verwendungen
DE60144013D1 (de) Harzzusammensetzung und verwendung derselben
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
DE60322022D1 (de) Strahlenhärtbare zusammensetzungen enthaltend copolymerisate von isobutylen und acrylmonomeren
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE60230883D1 (de) Neue formulierungen und ihre verwendung
ATE309987T1 (de) Substituierte benzamide und ihre verwendung als immunmodulatoren
ATE392416T1 (de) Tetrahydrochinolinderivate und deren verwendung als modulatoren des fsh rezeptors
DE69832173D1 (de) Zusammensetzungen zur oralen verabreichung von taxanen und deren verwendung